A Trial of Setmelanotide in Acquired Hypothalamic Obesity

Running, not enrolling · Phase 3 · Has a placebo group

Conditions studied: Hypothalamic Obesity

In brief

The goal of this trial is to learn how well Setmelanotide works to improve weight reduction, hunger, and quality of life in patients 4 years of age and older with acquired Hypothalamic Obesity (HO). To determine how well setmelanotide works and how safe it is, patients with HO will take a daily injection of either setmelanotide or placebo and complete trial assessments for 52 weeks on a therapeutic regimen. A separate sub-study in patients with congenital HO is detailed under NCT06760546.

Key facts

Study ID
NCT05774756
Run by
Rhythm Pharmaceuticals, Inc.
People needed
143
Starts
2023-04-26
Expected to finish
2027-04-16
Last updated by the study team
2026-05-29

Who can join

Age: 4 and older. Sex: any. Healthy volunteers: not accepted.

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.